



BLA 125522/S-009

**SUPPLEMENT APPROVAL**

Amgen, Inc.  
Attention: Adam Rupert  
Senior Manager, Regulatory Affairs  
One Amgen Center Drive, Mail Stop 17-2-B  
Thousand Oaks, CA 91320-1799

Dear Mr. Rupert:

Please refer to your Supplemental Biologics License Application (sBLA), dated and received November 8, 2016, submitted under section 351(a) of the Public Health Service Act for Repatha (evolocumab) injection.

This "Changes Being Effected" supplemental biologics application provides for revision to the Pushtronex™ On-Body Infusor with Prefilled Cartridge Instructions for Use (IFU) to add the following statement to the IMPORTANT section: "Children who are 13 to 17 years of age should use the on-body infusor and prefilled cartridge under adult supervision, as instructed by the healthcare provider."

**APPROVAL & LABELING**

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the IFU for the Pushtronex system) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Kati Johnson, Senior Regulatory Project Manager, at (301) 796-1234.

Sincerely,

*{See appended electronic signature page}*

James P. Smith, MD, MS  
Deputy Director  
Division of Metabolism and Endocrinology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

ENCLOSURE: Pushtronex™ On-Body Infusor with Prefilled Cartridge IFU

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JAMES P SMITH  
01/25/2017